DRG Epidemiology's coverage of osteoporosis comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of osteoporosis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology's osteoporosis forecast will answer the following questions:
- Of all people with osteoporosis, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with osteoporosis, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of osteoporosis over the forecast period?
- How will changes in the levels of exposure to known risk or protective factors affect the number of people at high-risk for hip-fracture or a major osteoporotic fracture?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following osteoporosis patient populations:
- Osteoporosis total prevalent cases
- Total prevalent cases by diagnosis
- Diagnosed prevalent cases by drug-treatment
Note: coverage may vary by country and region.
- Mature Markets
- Key Findings
- Total Prevalence of Osteoporosis per 1,000 Among People Aged 40+ in 2017 and 2037
- Relative Sizes of the Contributing Factors to the Trend in Osteoporosis Over the Next 20 Years
- Analysis of the Prevalent Cases of Osteoporosis in 2017 by Diagnosed and Drug-Treated Status
- Epidemiology Data
- Total Prevalent Cases
- Total Prevalent Cases - FRAX-High Risk
- Diagnosed Prevalent Cases
- Drug-Treated Prevalent Cases
- Reference Materials
- Literature Review
- Risk/Protective Factors
Author(s): Sunali D. Goonesekera, SM
Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.